1%盐酸布替萘芬乳膏治疗浅部真菌病临床观察

目的：评价1％盐酸布替萘芬乳膏治疗浅部真菌病的临床疗效及安全性，并与1％联苯苄唑凝胶进行比较。方法：对83例浅部真菌病患者进行治疗，其中治疗组43例，外用1％盐酸布替萘芬乳膏，每日1次；对照组40例，外用1％联苯苄唑凝胶，每日1次，体股癣疗程2周，手足癣4周。分别于停药及停药2周时观察记录患者的临床表现及治疗效果。结果：1％盐酸布替萘芬乳膏和1％联苯苄唑凝胶临床疗效相似，停药时临床总有效率分别为90．7％和90．0％，真菌总清除率为93．0％和90．0％；停药2周时临床总有效率分别为97．7％和92．5％，真菌总清除率为100．0％和92．5％。不良反应少。结论：1％盐酸布替萘芬乳膏治疗浅部真菌病疗效显著且安全。     

特比萘芬软膏与疗霉舒软膏随机对照治疗浅部真菌病多中心临床研究

目的　比较研究山东齐鲁制药厂生产的１ ％ 特比萘芬软膏和诺华公司生产的１ ％ 疗霉舒软膏治疗浅部真菌病的有效性和安全性。方法　随机、多中心临床研究。两种药物的用药剂量和疗程相同，外涂患处，每日２ 次，体股癣、花斑癣疗程１ 周，手足癣和皮肤念珠菌病疗程２ 周。结果　１ ％ 特比萘芬软膏治疗浅部真菌病，临床治愈率为７０ ．８ ％ ，总有效率９６ ．２ ％ ，真菌清除率为９０ ．６ ％ ，不良反应发生率０ ．９ ％ ；对照组疗霉舒临床治愈率为７４ ．５ ％ ，总有效率９７ ．１ ％ ，真菌清除率为９３ ．１ ％ ，不良反应发生率为２ ．０ ％ 。两种药物治疗浅部真菌病的临床疗效和安全性在统计学上差异均无显著性意义。结论１ ％ 特比萘芬软膏治疗浅部真菌病疗效好、安全性高，与１ ％ 疗霉舒软膏比较疗效相似。     

1%环吡酮胺软膏治疗浅部真菌病的疗效观察

目的 :评价环吡酮胺软膏治疗皮肤浅部真菌病的疗效和安全性。方法 :1 3 0例浅部真菌病分成二组 ,治疗组外用环吡酮胺软膏 ,对照组外用特比萘芬乳霜 ,体股癣疗程 2周 ,手足癣疗程 4周。结果 :治疗组 66例中治愈 42例 ,显效 1 8例 ,临床总有效率 90 91 % ,真菌清除率 89 3 9% ;对照组总有效率为 92 1 9% ,真菌清除率为 90 63 % ,两组疗效差异无显著性 (P >0 0 5 )。结论 :环吡酮胺软膏治疗皮肤浅部真菌病疗效显著且安全     

国产特比萘芬治疗皮肤浅部真菌病的疗效观察

目的：为了解国产特比萘芬治疗皮肤浅部真菌病的疗效和安全性。方法：用国产特比萘芬治疗107例皮肤浅部真菌病（特比萘芬250mg,口服，1d1次，体股癣连用2w；手足癣连用3w；甲癣连服1周后改隔日顿服，共12w-20w)。结果：停药时痊愈86例，显效14例，进步5例，无效2例。停药时治疗率为80．4％，有效率为93．5％，真菌消除率为97.2%。结论：国产特比萘芬治疗皮肤浅部真菌病疗效好、副作用少。     

特比萘芬软膏与疗霉舒软膏随机对照治疗浅部真菌病多中…

目的 比较研究山东齐鲁制药厂生产的１％特比萘芬软膏和诺华公司生产的１％疗霉舒软膏治疗浅部真菌病的有效性和安全性。方法 随机、多中心临床研究。两种药物的用药剂量和疗程相同，外涂患外，每日２次，体股癣、花斑癣疗程１周，手足癣和皮肤念珠菌病疗程２周。结果 １％特比萘芬软膏治疗浅部真菌病，临床治愈率为７０．８％，总有效率９６．２％，真菌清除率为９０．６％，不良反应发生率０．９％；对照组疗霉舒临床治愈率为７     

1%盐酸特比萘芬乳膏治疗浅部真菌感染的疗效观察

目的：观察1％盐酸特比萘芬乳膏治疗浅部真菌感染的疗效及安全性。方法：对门诊78例经临床及真菌镜检诊断为股癣，手足癣及花斑癣的病人，每天2次使用1％盐酸特比萘芬乳膏外搽，疗程2周，治疗开始及治疗结束2周后进行症状及体征评分和真菌学镜检，治疗结束随访时同时对病人进行满意度调查。共对随访资料完整的78例病人的治疗结果进行了总结。结果：1％盐酸特比萘芬乳膏治疗手足癣的总有效率为94．1％，对股癣总有效率为96％，对花斑癣总有效率为89．5％。病人总体满意度方面表示非常好和很好的比例为84．6％。没有记录到治疗有关的副作用。结论：1％盐酸特比萘芬乳膏治疗皮肤真菌感染具有很高的临床有效率及依从性，安全性高，值得推广为治疗皮肤表皮癣菌的一线用药。     

国产伊曲康唑治疗皮肤浅部真菌病216例疗效观察

为观察国产伊曲康唑（美扶）治疗浅部真菌病的疗效。选择216例皮肤浅部真菌病患者，均口服美扶治疗，其中手足癣组口服美扶200mg，bid，连服7天；其余各组口服美扶200mg，qd，连服7天。停药3周评价疗效。结果：手足癣、体股癣、花斑癣、马拉色菌毛囊炎、念珠菌性包皮龟头炎和念珠菌性阴道炎总有效率分别为94．12％、97．47％、95．65％、81．25％、100％、81．25％。国产伊曲康唑治疗浅部真菌病疗效好、经济而安全。     

利拉萘酯乳膏治疗手足癣和体股癣40例疗效观察

目的：评价2％利拉萘酯乳膏手足癣与体股癣的临床疗效及安全性，并与l％联苯苄唑乳膏进行比较。方法：对74例浅部真菌病患者进行治疗，其中治疗组40例，外用2％利拉萘酯乳膏，每日1次；对照组34例，外用1％联苯苄唑乳膏，每日1次。手足癣疗程4周，体股癣疗程2周。分别于停药及停药后2周观察患者的临床表现及治疗效果。结果：2％利拉萘酯乳膏和1％联苯苄唑乳膏临床疗效相似，停药时临床总有效率分别为87．50％和85．29％；停药后2周临床总有效率分别为97．50％和91．17％，两组总有效率比较差异均无统计学意义（P均〉0．05），无不良反应。结论：2％利拉萘酯乳膏治疗手足癣和体股癣使用方便，依从性好，安全，有效，是值得推广的一种新型外用抗真菌药。     

1%联苯苄唑凝胶治疗皮肤浅部真菌病58例

目的：观察1％联苯苄唑凝胶治疗皮肤浅部真菌病的疗效。方法：入选110例皮肤浅部真菌病患者，随机分观察组58例，外用1％联苯苄唑凝胶，每日1次；对照组52例，外用1％盐酸特比萘芬乳膏，每日2次，两组疗程均3周，比较其临床疗效。结果：治疗组痊愈率及总有效率与对照组无统计学意义（X^2值分别为0．03及0．01，P均〉0．05）。结论：1％联苯苄唑凝胶治疗皮肤癣菌病疗效肯定，安全性高，可作为临床常规选用外用药之一。     

盐酸布替萘芬软膏治疗浅部真菌病疗效观察

目的探讨盐酸布替萘芬软膏治疗浅部真菌病的临床疗效。方法使用1%盐酸布替萘芬软膏,早、晚各1次薄薄涂于患处,1～4周判断疗效;并以克霉唑软膏作对照。结果盐酸布替萘芬软膏治疗体股癣痊愈率59.01%,有效率和真菌清除率均95.45%;治疗手足癣痊愈率为44.44%,有效率为92.60%,真菌清除率为88.89%;治疗花斑癣痊愈率为56.25%,有效率为93.75%,真菌清除率93.75%。各病种治疗组与对照组治愈率、有效率及真菌清除率分别比较,差异均有统计学意义(P均<0.05)。结论盐酸布替萘芬软膏治疗浅部真菌病安全、有效。     

Comparative study between terbinafine 1% emulsion-gel versus ketoconazole 2% cream in tinea cruris and tinea corporis

An open, prospective, comparative, randomised and parallel-group study of 65 patients was conducted to evaluate the efficacy and safety of topical 1 % emulsion-gel of terbinafine versus 2% ketoconazole cream in the treatment of tinea corporis and tinea cruris. Treatment for terbinafine emulsion-gel was applied once daily for 1 week, whereas ketoconazole cream was applied once daily for 2 weeks; patients were followed for 2 weeks. Thirty-three patients in the terbinafine group and 32 in the ketoconazole group were evaluated for efficacy and safety. At the end of the study, rates of mycological cure were 94% for terbinafine emulsion-gel and 69% for ketoconazole cream (p = 0.027). A clinical and mycological overall evaluation was obtained for 72% of patients receiving terbinafine emulsion gel and 31% of patients receiving ketoconazole cream (p = 0.002). A total of four patients (1 in the terbinafine group and 3 in the ketoconazole group) had contact dermatitis-like side effects. We conclude that a 1-week course of terbinafine 1% emulsion-gel is significantly more effective than ketoconazole 2% cream in the treatment of tinea corporis and tinea cruris as regards clinical and mycological cure and treatment safety.     

特比萘芬超声透入治疗头癣的临床研究

目的 :　评价特比萘芬超声透入治疗头癣的疗效和安全性 ,探索头癣治疗新方法。方法 :　按标准选取头癣患者 4 5例。皮损处及其周围 1cm范围剃发 ,用 1%特比萘芬霜均匀涂抹 ,用超声治疗仪透入治疗 ,超声频率 80 0kHz,声强 0 .75W cm2 ,移动法 ,15分钟 ,每周两次 ,共 4周。于 0、2、4、8周末进行临床评分和真菌学检查 ,于 8周末评价疗效和安全性、并与我们 1999年做的口服特比萘芬 4周治疗头癣的试验结果进行比较。结果 :　 36例患者按要求完成试验 ,病原菌包括犬小孢子菌 2 9株 (80 .6 % ) ,须癣毛癣菌 7株 (19.4 % )。 4周末超声组与口服组治愈率分别为 33.3%和 5 1.9% ,χ2 =2 .18,P >0 .0 5 ;8周末超声组与口服组治愈率分别为 6 3.9%和 88.9% ,χ2 =5 .0 8,P <0 .0 5。超声透入治疗未见副作用发生 ,而口服组 2例发生轻度副作用。结论 :　特比萘芬超声透入疗法治疗头癣有较好的疗效和很好的安全性 ,但比口服特比萘芬的疗效稍差 ,超声透入疗法的最适条件、疗程和操作方法尚需进一步研究     

特比萘芬治疗儿童头癣59例疗效和安全性评价

目的探讨特比萘芬治疗儿童头癣的疗效及安全性。方法将59例患儿随机分为两组,治疗组口服特比萘芬,同时采用剃发、洗头、搽药、用具消毒、日晒等方法治疗;对照组仅口服特比萘芬。两组的疗程均为12周。结果治疗组临床治愈率为79.31%,真菌学治愈率为72.41%,完全治愈率为68.97%;对照组依次为50.00%,46.67%和36.67%。未达真菌学治愈的真菌菌种以犬小孢子菌居多,共19(32.20%)例。结论剃发、洗头、擦药、用具消毒、日晒同时口服特比萘芬可明显提高头癣的完全治愈率。     

Efficacy and tolerability of 8 weeks'' treatment with terbinafine in children with tinea capitis caused by Microsporum canis: a comparison of three doses

BACKGROUND: Tinea capitis caused by Microsporum canis is the most common mycosis of the scalp in preschool and school-aged children in Greece. OBJECTIVE: To compare the efficacy, safety and tolerability of an 8-week course of oral terbinafine at different doses. METHODS: Patients received oral terbinafine at doses ranging from 3.3 to 12.5 mg/kg/day for 8 weeks, as follows: group A, terbinafine 3.3 to 6.0 to 7.0 mg/kg/day (23 patients); group C, terbinafine > 7.0 to 12.5 mg/kg/day (37 patients). Fungal microscopy and cultures were performed 4 weeks before the start of the treatment, at the end of the treatment (week 8) and at a follow-up visit at week 16. RESULTS: At week 8 mycological cure was achieved in one patient (2.7%) in group A, in 21 patients (91.3%) in group B and in 34 patients (97.1%) in group C. At week 16 mycological cure was achieved in one patient (2.7%) in group A, in 22 patients (95.7%) in group B and in 35 patients (100%) in group C. There was a statistically significant difference (P < 0.0005) between dose level and efficacy of terbinafine at the end of the treatment period and also at the follow-up visit at week 16. Five patients (three in group A and two in group C) discontinued treatment because of adverse events. CONCLUSIONS: The administration of terbinafine at a dose of either 6-7 or 7-12.5 mg/kg/day for 8 weeks is safe and effective for the treatment in children of tinea capitis caused by M. canis.     

Terbinafine: efficacy and tolerability in young children with tinea capitis due to Microsporum canis

AIMS: We carried out an open, prospective, uncontrolled study to evaluate the efficacy and tolerability of terbinafine in the treatment of young children with tinea capitis due to Microsporum canis. METHODS: A total of 83 healthy, immunocompetent children (age range 2-13 years) were enrolled in eight centres in Estonia, Latvia and Lithuania. Patients received oral terbinafine in dosages based on weight, 62.5 mg for those weighing 10-20 kg, 125 mg for 20-40 kg, plus application of topical 1% terbinafine cream twice daily to affected areas. Treatment lasted for 4 weeks, followed by an 8-week observation (treatment-free) period. All the subjects were assessed for efficacy and tolerability at 12 weeks. RESULTS: Eighty-one subjects were available for assessment at 12 weeks: 32 had completely recovered, with no evidence of relapse during the observation period, and 21 showed mycological cure, but presented residual physical signs of infection. Thus the effective cure rate was 65.4% in an infection known to be more difficult to cure than other causes of tinea capitis. Terbinafine was well tolerated by these children. CONCLUSIONS: This study showed effective cure of two-thirds of 81 cases of tinea capitis caused by M. canis with a 4-week course of treatment. As one-third of the cases did not respond to treatment, we suggest using combined oral and topical treatment with terbinafine in children with tinea capitis caused by M. canis.     

Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis or tinea cruris

Two randomized, double-blind, vehicle-controlled, multicenter studies assessed the efficacy and safety of a new terbinafine 1% solution for the treatment of interdigital tinea pedis and tinea corporis or tinea cruris (tinea corporis/cruris). Patients with interdigital tinea pedis applied terbinafine 1% solution or vehicle twice daily for 1 week with 7 weeks of follow-up (N = 153), and patients with tinea corporis/cruris applied terbinafine 1% solution or vehicle once daily for 1 week with 3 weeks of follow-up (N = 66). Efficacy was assessed mycologically and clinically at the end of treatment and throughout follow-up. In the tinea pedis study, 66% of patients were effectively treated with terbinafine compared with 4% of the group treated by vehicle (P < .001; Mantel-Haenszel test). In the tinea corporis/cruris study, treatment was effective in 65% of the terbinafine group compared with 8% of the vehicle group (P < .001). There were no significant differences in the frequency of cutaneous adverse events between the 2 groups in either study. We conclude that one week of therapy with terbinafine 1% solution is highly effective, superior to vehicle, and safe for use in superficial fungal infections.     

A randomized,double-blind,parallel-group,duration-finding study of oral terbinafine and open-label,high-dose griseofulvin in children with tinea capitis due to Microsporum species

BACKGROUND: Tinea capitis, a common clinical pattern of dermatophyte infection in children is becoming a public health hazard in some countries. Several studies have reported terbinafine to be a safe and well-tolerated fungicidal drug for the treatment of this infection. However, the optimal treatment duration for its use in the treatment of tinea capitis caused by Microsporum species has not yet been determined. OBJECTIVE: (i) To establish the optimal duration for terbinafine treatment to bring about complete cure of tinea capitis due to Microsporum infection in a large paediatric population, and (ii) to obtain information on the maximum therapeutic effect of the existing therapy. PATIENTS AND METHODS: This parallel-group, double-blind, multicentre study was conducted in Europe and South America. Patients were randomized to one of four oral terbinafine treatment arms (6, 8, 10 or 12 weeks treatment) or to an open label, 12-week, high-dose griseofulvin (20 mg x kg(-1) x day(-1)) arm at a 1 : 1 : 1 : 1 : 1 ratio. All patients were followed up for 4 weeks after the end of the treatment phase. RESULTS: In this group of 134 intention-to-treat patients, effective treatment was observed at the end of study in 62% of patients treated with terbinafine for 6 weeks and in 63% treated for 8 weeks. Mycological cure was obtained in 59% and 57%, respectively, and clinical cure in 76% and 80%. In the griseofulvin group, effective treatment was 88%, mycological cure was 76% and clinical cure 96%. However, these high rates were believed to be due to the high dosage of this drug and the prolonged course of treatment. Complete cure was observed at the end of study in 62% patients treated with terbinafine for 6 weeks, in 60% treated for 8 weeks and in 84% patients treated with griseofulvin for 12 weeks. CONCLUSIONS: Although there was no statistical trend between the duration of terbinafine treatment within the groups for complete cure at the end of study, there was a positive correlation between the daily dose of terbinafine (mg x kg(-1)) and complete cure. Terbinafine therapy for 6 weeks could represent an alternative to griseofulvin for the treatment of Microsporum tinea capitis. However, further clinical trials are required in order to optimize the dose regimen to allow higher cure rates to be reached.